Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Salbutamol MDI - GSK

Next Previous
Drug Profile

Salbutamol MDI - GSK

Alternative Names: AH-3365; Albuterol; Albuterol HFA; albuterol hydrofluoroalkane; salbutamol (albuterol) MDI; salbutamol - metered dose; Salbutamol HFA; Salbutamol hydrofluoroalkane; salbutamol pressurised inhalation; Salbutamol sulfate MDI - GlaxoSmithKline; Ventolin

Latest Information Update: 17 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GSK
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Phenols; Small molecules; Tocolytics
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Asthma
  • Phase I Transient tachypnoea of the newborn

Most Recent Events

  • 31 Dec 2024 GSK in collaboration with Khyber Teaching Hospital completes the phase I trial in Transient tachypnea of the newborn (In neonates) in Pakistan (PO) (NCT06921291)
  • 23 Oct 2024 GlaxoSmithKline completes a phase I trial in Asthma (In volunteers) in Netherlands (PO) (NCT06433908)
  • 14 Aug 2024 Phase-I clinical trials in Asthma (Treatment-experienced) in Bulgaria, Germany, Poland, Romania, United Kingdom (PO) (NCT06433921) (EUCT2024-511220-14-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top